Our website uses cookies to make navigation as functional as possible and to perform statistics on its usage. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here. By continuing to browse this website, you will be accepting our cookies.

Commitment to Transparency

Although we are clearly invested in bringing new and improved pharmacological treatments to market, our policy is to champion a broad scope of education and improvement initiatives. Any support provided is in strict adherence to legislation, the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice for the Pharmaceutical Industry and A.Menarini’s internal policies. All support granted is subject to stringent internal audit to ensure compliance with these requirements and published appropriately.


The donations and grants outlined here constitute payments referred to as transfers of value (ToV).

As part of a move towards greater transparency and with the aim of building better relationships with the medical community and wider stakeholders, pharmaceutical companies are required to disclose certain payments to, or for the benefit of, individual Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs). This is an industrywide initiative with IPHA, our self-regulatory body in Ireland and across the EU under EFPIA.

This disclosure will be made on a central platform hosted by IPHA within 6 months of the end of the year in which the transfer takes place. Therefore, the disclosure of 2017 items will be made by 30th June 2018. Further information on the disclosure of ToV can be found on the IPHA website: www.ipha.ie

If you decide to apply for support, to enable us to comply with our regulatory requirements, we request that you agree that your details will be stored on our database, or those of other affiliates, and used for publicly reporting payments or other transfers of value made by us to you for activity after January 1st 2015 as required by our industry Code of Practice. A.Menarini fully supports the transparency of ToV payments and we hope you will agree. You can contact us at anytime to exercise your rights to opt-out of public disclosure.

Quality first

Quality: point of departure and arrival for our drugs.


Menarini in the world

The Menarini Group has companies located almost all over the world.


Innovation & Research

Constant commitment to new drug research.


Our values


10 core values have influenced the progress of our group.